HCPCS Code Applications and Approvals: April 2026
Quarterly archive · CMS Level II HCPCS35 coding decisions took effect April 1, 2026
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Fourth Quarter 2025 coding cycle, which took effect April 1, 2026.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
April 2026
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| C9145 | APONVIE 505(b)(2) Injection, aprepitant, (aponvie), 1 mg | Heron Therapeutics, Inc. Intravenous | Replaced byJ8502 | Discontinue | |
| C9307 | LYNOZYFIC Injection, linvoseltamab-gcpt, 1 mg | Regeneron Pharmaceuticals, Inc. Intravenous | Replaced byJ9601 | Discontinue | |
| C9308 | KYXATA 505(b)(2) Injection, carboplatin (avyxa), 1 mg | AVYXA Pharma, LLC Intravenous | Replaced byJ9278 | Discontinue | |
| J0174 | LEQEMBI Lecanemab-irmb, for intravenous injection, 1 mg | Eisai Inc. Intravenous | — | Revise | |
| J0463 | Atropine Sulfate (Fresenius and Therapeutically Equivalent) Injection, atropine sulfate (fresenius and therapeutically equivalent), 0.01 mg | — | — | Establish | |
| J1098 | CYKLX 505(b)(2) Articaine ophthalmic, 8% solution, 0.4 ml | American Genomics, LLC Ophthalmic | — | Establish | |
| J1164 | Diltiazem Hydrochloride In 0.72% Sodium Chloride Injection, diltiazem hydrochloride in 0.72% sodium chloride, 0.5 mg | — | — | Establish | |
| J1553 | Immune Globulin (Yimmugo) Injection, immune globulin (yimmugo), 100 mg | — | — | Establish | |
| J3404 | PAPZIMEOS Injection, zopapogene imadenovec-drba suspension, per therapeutic dose | Precigen, Inc. Subcutaneous | — | Establish | |
| J8502 | APONVIE 505(b)(2) Injection, aprepitant (aponvie), 1 mg | Heron Therapeutics, Inc. Intravenous | ReplacesC9145 | Establish | |
| J9003 | CAMCEVI ETM 505(b)(2) Leuprolide injectable (camcevi etm), 1 mg | Accord Biopharma, Inc. | — | Establish | |
| J9183 | INLEXZO 505(b)(2) Gemcitabine intravesical system, 225 mg | Johnson & Johnson Healthcare Systems Inc. Intravesical | — | Establish | |
| J9277 | KEYTRUDA QLEX Injection, pembrolizumab, 1 mg and berahyaluronidase alfa-pmph | Merck Subcutaneous | — | Establish | |
| J9278 | KYXATA 505(b)(2) Injection, carboplatin (avyxa), 1 mg | AVYXA Pharma, LLC Intravenous | ReplacesC9308 | Establish | |
| J9601 | LYNOZYFIC Injection, linvoseltamab-gcpt, 1 mg | Regeneron Pharmaceuticals, Inc. Intravenous | ReplacesC9307 | Establish | |
| Q0238 | TYENNE Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg | Fresenius Kabi Intravenous | — | Establish | |
| Q4418 | BioLab Membrane Wrap Flow Biolab membrane wrap flow, per square centimeter (add-on, list separately in addition to primary procedure) | BioLab Holdings Topical | — | Establish | |
| Q4419 | BioLab Membrane Wrap -Lite Flow Biolab membrane wrap lite flow, per square centimeter (add-on, list separately in addition to primary procedure) | BioLab Holdings Topical | — | Establish | |
| Q4421 | BioLab Membrane Wrap- Solo Biolab membrane wrap solo, per square centimeter (add-on, list separately in addition to primary procedure) | BioLab Holdings Topical | — | Establish | |
| Q4422 | A/C Wrap A/c wrap, per square centimeter (add-on, list separately in addition to primary procedure) | BioLab Holdings Topical | — | Establish | |
| Q4423 | BioLab Tri-Membrane Wrap Flow Biolab tri-membrane wrap flow, per square centimeter (add-on, list separately in addition to primary procedure) | BioLab Holdings Topical | — | Establish | |
| Q4424 | Revive FT Revive ft, per square centimeter (add-on, list separately in addition to primary procedure) | Acesso Biologics LLC dba Dynamic Medical Services | — | Establish | |
| Q4425 | Revive TL Revive tl, per square centimeter (add-on, list separately in addition to primary procedure) | Acesso Biologics LLC dba Dynamic Medical Services | — | Establish | |
| Q4426 | DermaBind TL + Dermabind tl + or dermabind tl x, per square centimeter (add-on, list separately in addition to primary procedure) | HealthTech Wound Care | — | Establish | |
| Q4427 | DermaBind DL N Dermabind dl n or dermabind dl + or dermabind dl x, per square centimeter (add-on, list separately in addition to primary procedure) | HealthTech Wound Care | — | Establish | |
| Q4428 | DermaBind SL N Dermabind sl n or dermabind sl + or dermabind sl x, per square centimeter (add-on, list separately in addition to primary procedure) | HealthTech Wound Care | — | Establish | |
| Q4429 | DermaBind CH N Dermabind ch n or dermabind ch x, per square centimeter (add-on, list separately in addition to primary procedure) | HealthTech Wound Care | — | Establish | |
| Q4435 | Renati Membrane Renati membrane, per square centimeter (add-on, list separately in addition to primary procedure) | Pinnacle Transplant Technologies | — | Establish | |
| Q4436 | Renati AC Membrane Renati ac membrane, per square centimeter (add-on, list separately in addition to primary procedure) | Pinnacle Transplant Technologies | — | Establish | |
| Q4437 | REVIVALAC Revival ac, per square centimeter (add-on, list separately in addition to primary procedure) | Samaritan Biologics LLC | — | Establish | |
| Q4438 | Pretect Pretect, per square centimeter (add-on, list separately in addition to primary procedure) | Stimlabs LLC | — | Establish | |
| Q4439 | InstaGraft Instagraft, per square centimeter (add-on, list separately in addition to primary procedure) | Xtant Medical | — | Establish | |
| Q4440 | CuraMatrix Curamatrix, per square centimeter (add-on, list separately in addition to primary procedure) | Xtant Medical | — | Establish | |
| Q5161 | AUKELSO/BOSAYA Biosimilar Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg | Biocon Biologics Inc. Subcutaneous | — | Establish | |
| Q5162 | BILDYOS/BILPREVDA Biosimilar Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg | Organon LLC Subcutaneous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Fourth Quarter 2025 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
